Altimmune, Inc.
A clinical-stage biopharmaceutical company developing pemvidutide, a balanced GLP-1 and glucagon dual receptor agonist in late-stage trials for fatty-liver disease (MASH), alcohol use disorder, and alcohol-associated liver disease. It began in 1997 as vaccine maker Vaxin Inc. before renaming to Altimmune in 2015, and its early work included NasoVAX, a needle-free intranasal flu vaccine.
Bought 555.0K
Bought 430.0K
Bought 125.0K
Bought 15.0K · Sold 1.35M
Bought 125.0K
Bought 2.80M
Bought 560.0K · Sold 280.5K
Sold 200.0K
Granted 1.32M
Sold 215.5K
Granted 1.26M · Bought 20.0K · Sold 341.1K
Granted 150.0K · Bought 875.1K · Sold 498.0K
Bought 150.0K
Granted 699.3K · Bought 20.0K · Sold 35.0K
Granted 37.2K · Bought 160.5K
Granted 364.5K · Bought 1.3K
Granted 180.0K · Bought 25.0K
Granted 160.0K · Bought 37.9K
Granted 126.3K
Granted 285.1K · Bought 449 · Sold 80.0K
Granted 134.4K · Bought 10.0K · Sold 34.0K
Granted 89.5K
Granted 79.8K · Bought 21.5K · Sold 16.0K
Bought 47.5K
Granted 49.3K
Granted 43.3K · Bought 10.0K
Granted 61.7K · Sold 22.4K
Granted 16.9K · Sold 9.7K
Granted 18.8K · Bought 25.0K
Granted 40.7K
Granted 23.3K
Granted 38.1K
Granted 29.8K · Bought 10.0K
Granted 29.6K · Bought 10.0K · Sold 29.6K
Granted 295.8K · Bought 10.1K
Granted 839.1K · Bought 22.7K · Sold 11.1K
Granted 17.7K
Bought 15.0K
Granted 36.9K · Bought 7.0K · Sold 30.4K
Granted 1.3K
Granted 23.1K · Bought 2.0K · Sold 10.2K
Granted 25.0K
Bought 2.5K
Bought 1.5K
Granted 17.6K · Bought 527 · Sold 17.6K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Evnin Luke +6 co-filers10% owner · 4 transactions | — | 12.27Mas of Nov 2010 | — | 555.0K | — |
| MPM Asset Management Investors 2004 BVIII LLC +6 co-filers10% owner · 2 transactions | — | 12.27Mas of Nov 2010 | — | 430.0K | — |
| Novartis Ag +1 co-filer10% owner · 15 transactions | — | 8.35Mas of Sep 2018 | — | — | — |
| MPM Asset Management Investors 2004 BVIII LLC +6 co-filers10% owner · 2 transactions | — | 6.98Mas of Aug 2007 | — | 125.0K | — |
| Frohlich Phil +1 co-filer10% owner · 5 transactions | — | 6.63Mas of Dec 2016 | — | 15.0K | 1.35M |
| Cavanaugh James H +6 co-filersDirector, 10% owner, 10% owner · 3 transactions | — | 4.25Mas of Nov 2010 | — | 125.0K | — |
| Koh Bong Y +7 co-filers10% owner · 8 transactions | — | 3.50Mas of Feb 2021 | — | 2.80M | — |
| Pappajohn JohnDirector · 20 transactions | — | 1.75Mas of May 2011 | — | 560.0K | 280.5K |
| Velocity Pharmaceutical Holdings LLC10% owner · 2 transactions | — | 1.69Mas of May 2020 | — | — | 200.0K |
| Hodges Philip +3 co-filersDirector, 10% owner · 3 transactions | — | 1.32Mas of May 2017 | 1.32M | — | — |
| Englander Israel A +2 co-filers10% owner · 11 transactions | — | 1.20Mas of Aug 2007 | — | — | 215.5K |
| Truffle Capital S.A.S.10% owner · 18 transactions | — | 833.1Kas of Feb 2018 | — | — | — |
| Richman Eric IDirector · 34 transactions | — | 732.4Kas of Nov 2016 | 1.26M | 20.0K | 341.1K |
| Schaffer Derace LDirector · 56 transactions | — | 601.8Kas of Jan 2018 | 150.0K | 875.1K | 498.0K |
| Kinley Matthew PFormer President & Treasurer · 12 transactions | — | 541.0Kas of Aug 2007 | — | 150.0K | — |
| Garg Vipin KDirector · 76 transactions | — | 424.5K | 699.3K | 20.0K | 35.0K |
| Wright David PPresident and CEO, Director · 14 transactions | — | 399.5Kas of Dec 2009 | 37.2K | 160.5K | — |
| Enright WilliamPresident and CEO, Director · 5 transactions | — | 365.8Kas of May 2018 | 364.5K | 1.3K | — |
| St Peter StevenDirector · 11 transactions | — | 205.0Kas of Jan 2017 | 180.0K | 25.0K | — |
| Runge Jeffrey W.Director · 10 transactions | — | 197.7Kas of Jan 2017 | 160.0K | 37.9K | — |
| Macneill PhilipVP, CFO, Treasurer, Secretary · 10 transactions | — | 126.3Kas of Dec 2016 | 126.3K | — | — |
| McCleary JoelDirector · 1 transaction | — | 120.2Kas of Nov 2010 | — | — | — |
| Roberts M ScotChief Scientific Officer · 53 transactions | — | 112.8K | 285.1K | 449 | 80.0K |
| Harris Matthew ScottChief Medical Officer · 36 transactions | — | 83.9Kas of Aug 2025 | 134.4K | 10.0K | 34.0K |
| Jordt Raymond MChief Business Officer · 18 transactions | — | 70.1K | 89.5K | — | — |
| Drutz DavidDirector · 16 transactions | — | 55.5Kas of Aug 2024 | 79.8K | 21.5K | 16.0K |
| Durso Jerome BenedictPresident and CEO, Director · 3 transactions | — | 47.5K | — | 47.5K | — |
| Camut Christopher CVP, Gov't Contracts · 3 transactions | — | 46.8Kas of Jan 2010 | 49.3K | — | — |
| Eisenstadt Richard IChief Financial Officer · 11 transactions | — | 45.0Kas of Jan 2024 | 43.3K | 10.0K | — |
| Riddle Valerie DSVP, Medical Director · 12 transactions | — | 44.4Kas of May 2011 | 61.7K | — | 22.4K |
| Hodges PhilipDirector · 4 transactions | — | 41.3Kas of Mar 2021 | 16.9K | — | 9.7K |
| Weaver Gregory LChief Financial Officer · 5 transactions | — | 38.1K | 18.8K | 25.0K | — |
| Cook Francesca MSVP, Policy & Gov't Affairs · 5 transactions | — | 37.6Kas of Jan 2012 | 40.7K | — | — |
| Fusco JoanSenior VP, Operations · 3 transactions | — | 36.7Kas of Mar 2010 | 23.3K | — | — |
| Morges WayneVP, Regulatory Affairs & Qual · 3 transactions | — | 35.5Kas of Jan 2010 | 38.1K | — | — |
| Karp Jordan PSVP, General Counsel · 4 transactions | — | 31.9Kas of Jan 2012 | 29.8K | 10.0K | — |
| Chang Linda LSVP, CFO & Secretary · 3 transactions | — | 30.0Kas of Jan 2015 | 29.6K | 10.0K | 29.6K |
| Sayare MitchelDirector · 13 transactions | — | 26.4Kas of Sep 2020 | 295.8K | 10.1K | — |
| Gill JohnDirector · 18 transactions | — | 21.7K | 839.1K | 22.7K | 11.1K |
| Brown William MichaelChief Financial Officer · 4 transactions | — | 17.7Kas of Jul 2021 | 17.7K | — | — |
| Fuerst Thomas RichardSVP, Chief Scientific Officer · 2 transactions | — | 15.0Kas of Nov 2011 | — | 15.0K | — |
| Pisano WayneDirector · 6 transactions | — | 13.5K | 36.9K | 7.0K | 30.4K |
| Shutterly AndrewActing Chief Financial Officer · 1 transaction | — | 11.4Kas of Jul 2024 | 1.3K | — | — |
| Schafer KlausDirector · 7 transactions | — | 9.0Kas of Jun 2022 | 23.1K | 2.0K | 10.2K |
| Jones Jeffrey MichaelCOO · 1 transaction | — | 2.5Kas of Mar 2015 | 25.0K | — | — |
| Price KevinPresident-Pharmathene UK, Ltd. · 1 transaction | — | 2.5Kas of Nov 2008 | — | 2.5K | — |
| Sohn Catherine A.Director · 2 transactions | — | 1.5K | — | 1.5K | — |
| Jorkasky DianeDirector · 3 transactions | — | 527 | 17.6K | 527 | 17.6K |
| Hodges Philip +1 co-filerDirector · 1 transaction | — | 0as of Oct 2017 | — | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +2.91M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.